Anne Lesage Sells 21,700 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anne Lesage sold 21,700 shares of the stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total transaction of $656,642.00. Following the transaction, the insider owned 56,450 shares of the company’s stock, valued at $1,708,177. This trade represents a 27.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Anne Lesage also recently made the following trade(s):

• On Wednesday, April 29th, Anne Lesage sold 3,700 shares of Pharvaris stock. The shares were sold at an average price of $30.08, for a total transaction of $111,296.00.
• On Thursday, April 30th, Anne Lesage sold 19,200 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total transaction of $580,992.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $210,350.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,500 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $225,375.00.
• On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total transaction of $3,003.00.

Pharvaris Price Performance

PHVS stock traded down $1.57 during trading on Friday, hitting $29.44. 512,191 shares of the company’s stock traded hands, compared to its average volume of 245,049. Pharvaris N.V. has a 52 week low of $14.59 and a 52 week high of $31.14. The business has a fifty day simple moving average of $27.62 and a 200 day simple moving average of $26.03.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Analysts anticipate that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.

Institutional Trading of Pharvaris

A number of institutional investors have recently modified their holdings of the company. Seven Fleet Capital Management LP bought a new stake in shares of Pharvaris in the 4th quarter valued at about $1,536,000. XTX Topco Ltd boosted its holdings in shares of Pharvaris by 126.1% in the 4th quarter. XTX Topco Ltd now owns 18,568 shares of the company’s stock valued at $515,000 after buying an additional 10,355 shares in the last quarter. Ikarian Capital LLC boosted its holdings in shares of Pharvaris by 131.7% in the 4th quarter. Ikarian Capital LLC now owns 486,856 shares of the company’s stock valued at $13,510,000 after buying an additional 276,691 shares in the last quarter. Virtus Investment Advisers LLC boosted its holdings in shares of Pharvaris by 66.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 11,011 shares of the company’s stock valued at $306,000 after buying an additional 4,407 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new stake in shares of Pharvaris in the 4th quarter valued at about $634,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on PHVS shares. Wolfe Research started coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price on the stock. Wall Street Zen downgraded shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday, April 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Wedbush lifted their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Finally, Citigroup reissued a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and a consensus target price of $42.73.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.